Global Blood Therapeutics Inc. (NASDAQ: GBT) shares are -15.75% down in the year-to-date (YTD) period and have moved -7.87% or -$5.72 lower in the latest trading session. However, stock’s trailing 12-month performance remains nearly +8.37% lower. Comparatively, the stock is -23.50% down YTD and 20.38% over the trailing 3-month period. If we look at the shorter duration, its week performance is -5.32% and -16.01% over the month.
On November 25, 2019, Cantor Fitzgerald recommended the GBT stock is a Overweight, while earlier, SunTrust had Downgrade the stock as a Hold on January 31, 2020. 16 analysts offering the recommendations for the stock have a consensus rating of 1.90 to suggest that the GBT stock is a “Strong Sell”. 0 of the 16 analysts rate the stock as a “Sell”, while 0 has rated it as “Underweight”. 12 recommend buying, with 0 rating it as an Overweight.
The stock currently trades at $66.97 and analysts tracking its performance over the next 12 months have a consensus estimate price target of $101.44. The forecasts give the Global Blood Therapeutics Inc. stock a price target range of $150.00 on the higher side while at least one analyst think the stock could plunge to a low of $60.00. The consensus price target represents an upside potential 33.98 while the two limits represent an upside potential of 55.35% or -11.62%.
Analysts estimate the earnings to decrease -1.90% in the current quarter to -$1.24, down from the -$0.93 reported in the same quarter a year ago. For the current year, earnings should grow to an average of -$4.22 from -$3.41 reported last year. Analysts also offered guidance for the next financial quarter, with their average projected EPS at between -$1.44 and -$1.12. Wall Street estimates earnings per share to be at an average of -$4.42 for the next year.
Insider Transactions Summary
According to SEC data, total insider shares purchases at the company stands at 63 over the last 12 months, while SEC filings reveal that there have been 72 insider sales over the same period. Insiders have purchases 383,748 shares while those sold by company executives and officers stand at 399,900. The last 3 months have seen insiders trade a total of 240,339 and 315,355 in purchases and sales respectively.
Lehrer-Graiwer Joshua, a Chief Medical Officer at the company, sold 1,313 shares worth $91529.0 at $69.71 per share on Feb 18. The Chief Medical Officer had earlier traded another 1,313 GBT shares valued at $35320.0 on Feb 18. The shares were traded at $26.90 per share. LOVE TED W sold 4,007 shares at $70.54 per share on Feb 18 for a total of $282660.0 while Lehrer-Graiwer Joshua, (Chief Medical Officer) traded 625 shares on Feb 10 for $8094.0 with each share fetching $12.95.
Williams-Sonoma Inc. (NYSE:WSM), on the other hand, is trading around $68.74 with a market cap of $5.36B and analyst research firms have a negative stance on its shares. Analysts predict that the stock will reach $71.06 and spell out a more modest performance – a 3.26% return. Some analysts are even forecasting $4.74 per share in earnings this year on a short term (1 year) basis.
Let us briefly look at the Williams-Sonoma Inc. (WSM) financials, with a focus on its operating details as indicated in its earnings report for the last quarter.
Company balance sheet and cash flow
WSM’s operating margin was positive on the trailing 12 months basis, remaining steady at 7.90%, while the operating expenses over the recent quarter were at $416.58 million. This represented a 71.12% of the company’s total revenues which amounted $1.44 billion. With this in place, we can see that the company’s diluted EPS inclined $0.94 on the year-over-year period, growing to $1.00 as given in the last earnings report.
In terms of the balance sheet & cash flow as of (Jan 2020), the total assets figure advanced to $3.96 billion from $3.87 billion over the previous quarter. Total current assets were at $1.66 billion. The cash flow from operating activities totaled $89.95 million, significantly lower than the $179.5 million reported in the year-ago quarter. The company’s free cash flow for the quarter was $-31.2 million.
Insiders have transacted a total of 14 times at Williams-Sonoma Inc. over the last 6 months, with insider purchases undertaken 4 times and accounting for 108,587 shares. Insider sales totaled 140,706 shares over the same period, with these deals completed in 10 transactions. Looking at these numbers, we realize that net purchases over that period are -6.0 shares. Insiders now hold a total of 782.42k shares after the latest sales, with 2.50% net shares purchased.
Insiders own 0.60% of the company shares, while shares held by institutions stand at 76.67M. Investors are also buoyed by the number of investors in a company, with Williams-Sonoma Inc. having a total of 570 institutions that hold shares in the company. The top two institutional holders are Capital Research Global Investors with over 8.0 million shares worth more than $587.44 million. As of Dec 30, 2019, Capital Research Global Investors held 10.33% of shares outstanding.
The other major institutional holder is Vanguard Group, Inc. (The), with the investment firm holding over 7.33 million shares as of Dec 30, 2019. The firm’s total holdings are worth over $538.02 million and represent 9.46% of shares outstanding.